Serena Williams's comeback gained an ad placement, not a rules case. Front Office Sports reports that Ro bought Tennis Channel inventory around Williams's return at the HSBC Championships, where the 44-year-old entered doubles as a wild card alongside 19-year-old Canadian Victoria Mboko — and the pair beat the No. 3 seeds in straight sets in their first match. [1] The commercials and the comeback shared a broadcast. They did not share a rulebook.
That keeps the paper's June 18 line intact: the Williams return fit the wild-card and WADA rule frame before it became a morality play. It also follows the paper's June 17 account of the wild-card, comeback, and GLP-1 rule line and its June 16 note that the Williams sisters took a Wimbledon wild card. June 19 adds commercial machinery around the same comeback. It does not add a public ITIA charge, a WADA prohibition change, or a finding that rewrites the eligibility story.
The rule file is precise enough to quote. An ITIA spokesperson told Front Office Sports that GLP-1 medications are currently permitted for players but sit on WADA's monitoring program — semaglutide added in 2024, tirzepatide, the drug Williams has credited, following in 2025 — which tracks usage without sanctioning it and reviews substances annually for possible promotion to the Prohibited List. [1] [2] Monitoring is not permission forever; it is permission with a calendar attached. That distinction is exactly what X discourse flattens when it turns body change into evidence.
The commercial machinery deserves its own ledger, because it is more unusual than the doping chatter. Williams is a paid "celebrity patient ambassador" for Ro under a multi-year deal; her husband Alexis Ohanian sits on Ro's board; she says she lost roughly 31 pounds on the company's medication; the brand ran its first Super Bowl ad featuring her in February. [1] Now those ads run on the network broadcasting her matches. No governing body regulates that adjacency. The conflict-of-interest disclosures are public, the ad money is real, and none of it touches eligibility — which is precisely why the story keeps resolving into marketing coverage rather than a case number.
The distinction matters because sports discourse likes to turn body change into evidence. Williams's GLP-1 use, comeback timing, and television inventory are all fair subjects for coverage. [1] They are not the same thing as a doping violation. An ad buy can be opportunistic, lucrative, awkward, or revealing without becoming a rule breach.
MSM's business frame is cleaner than X's suspicion, but it also risks flattening the rule line into a marketing note. The ad market has noticed the comeback because Serena is Serena. X has noticed because GLP-1s have become shorthand for cheating, wellness, class, age, and recovery — one in eight American adults now takes the drug class, per KFF, so the suspicion is really about scale. [1] The article readers need keeps those categories separate.
The next real development would be documentary: an ITIA statement, a WADA list change, a tournament ruling, a sponsor disclosure, or a broadcast measurement record that changes the economics. Until then, the comeback is a commercial event running beside an eligibility file, not proof that the file is broken. Berlin starts Monday. The monitoring program reviews annually. Both calendars matter; neither has moved.
-- AMARA OKONKWO, Lagos